25% of Multiple Sclerosis patients, who are OCB negative test positive on free light chain production in CSF. 

As discussed in a recent publication by Professor Ferraro and colleagues(1) published by the European Journal of Neurology 

 

"Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis"

 

Get Your Free Access Copy Here 

 

Download Full Publication Here 

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system affecting approximately 2.5 million people globally.

Oligoclonal band analysis (OCB) is the standard for detecting intrathecal immunoglobulin synthesis in CSF to support MS diagnosis.

Free light chains are a new alternative biomarker to detect intrathecal immunoglobulin synthesis in CSF, helping to support an MS diagnosis. Compared to oligoclonal band (OCB) analysis, Free light chains analysis using Freelite offers:

  • Greater sensitivity and specificity (2-4)
  • Identification of OCB negative MS patients (3)
  • Prioritisation of high-risk patients by predicting CIS to MS conversion (5)

As discussed in a recent publication by Professor Ferraro and colleagues:

“FLC were also detected in the CSF of the small proportion of patients diagnosed with MS without OCB and in CIS patients, suggesting they may be a more sensitive marker of the disease”

“Kappa index values ≥ 5.8 were present at onset in 25% of 92 OCB-negative patients with suspected/possible MS who subsequently received a diagnosis of MS”

 

Discover Freelite Mx TM

Freelite Mx TM could simplify MS diagnosis (6)

 

CTA_Download Full Publication

Social media banners_Instagram

Freelite Mx TM is Quantitative

iStock-1189648868_web-min

Freelite Mx TM is Non-subjective

iStock-1194461946_web-min

Freelite Mx TM is Automated 

Medicine doctor hand working with modern computer interface as medical concept

Freelite Mxshould always be used in conjunction with other laboratory tests and clinical findings

 

CTA_Access Full Publication

 

References

  1. Ferraro D, Trovati A, Bedin R, Natali P, Franciotta D, Santangelo M, et al. Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. Eur J Neurol 2020;27:461-7.
  2. Presslauer S, Milosavljevic D, Brucke T, Bayer P, Hubl W. Elevated levels of kappa free light chains in csf support the diagnosis of multiple sclerosis. J Neurol 2008;255:1508-14.
  3. Presslauer S, Milosavljevic D, Huebl W, Parigger S, Schneider-Koch G, Bruecke T. Kappa free light chains: Diagnostic and prognostic relevance in ms and cis. PLoS ONE 2014;9:e89945.
  4. Presslauer S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, Krugluger W, Deisenhammer F, et al. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Mult Scler 2016;22:502-10.
  5. Brivio R, Galliani C, Spinoni N, Cavaletti G, Frigo M, Fusco L, Valsecchi C. Free light chains turbidimetric measurement in cerebrospinal fluid: Role in multiple sclerosis. Hematology Reports 2015;7:I142a.
  6. Agnello L, Lo Sasso B, Salemi G, Altavilla P, Pappalardo EM, Caldarella R, et al. Clinical use of kappa free light chains index as a screening test for multiple sclerosis. Lab Med 2020.